Evidence map›Paper›PMID 36577600›Full record

ReviewAtherosclerosis2023

Targeting and delivery of microRNA-targeting antisense oligonucleotides in cardiovascular diseases.

Goren Saenz-Pipaon, David A Dichek

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Atherosclerosis, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
3.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. mBiomolecules · 2026
    Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. miRNA in the Progression of Diabetic Kidney Disease: New Insight.International journal of molecular sciences · 2025
    Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Goren Saenz-PipaonDepartment of Medicine, University of Washington School of Medicine, Seattle, USA.
David A DichekDepartment of Medicine, University of Washington School of Medicine, Seattle, USA. Electronic address: ddichek@uw.edu.
University of Washington · US

Funding

Atheroprotective Gene TherapyR01HL114541 · NHLBI · UNIVERSITY OF WASHINGTON · PI DICHEK, DAVID A · 2013 to 2022
$4.9M
NHLBI NIH HHS R01 HL114541
6 · The paper itself

Abstract

Discovered three decades ago, microRNAs (miRNAs) are now recognized as key players in the pathophysiology of multiple human diseases, including those affecting the cardiovascular system. As such, miRNAs have emerged as promising therapeutic targets for preventing the onset and/or progression of several cardiovascular diseases. Anti-miRNA antisense oligonucleotides or "antagomirs" precisely block the activity of specific miRNAs and are therefore a promising therapeutic strategy to repress pathological miRNAs. In this review, we describe advancements in antisense oligonucleotide chemistry that have significantly improved efficacy and safety. Moreover, we summarize recent approaches for the targeted delivery of antagomirs to cardiovascular tissues, highlighting major advantages as well as limitations of viral (i.e., adenovirus, adeno-associated virus, and lentivirus) and non-viral (i.e., liposomes, extracellular vesicles, and polymer nanoparticles) delivery systems. We discuss recent preclinical studies that use targeted antagomir delivery systems to treat three major cardiovascular diseases (atherosclerosis, myocardial infarction, and cardiac hypertrophy, including hypertrophy caused by hypertension), highlighting therapeutic results and discussing challenges that limit clinical applicability.

Indexed as

Cardiovascular DiseasesMicroRNAsHeartHumansOligonucleotidesOligonucleotides, AntisenseMicroRNAsOligonucleotidesOligonucleotides, AntisenseAntagomirCardiovascular diseasesEncapsulationmicroRNATargeted delivery

Identifiers

PMID36577600
PMCPMC10277317
OpenAlexW4312056723

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.